Munich-based oncology company Tubulis closed a €308 million (USD 361M) Series C round led by Venrock Healthcare Capital Partners, with participation from new investors Wellington Management and Ascenta Capital and existing backers including Nextech Invest, EQT Life Sciences, Frazier Life Sciences and others.
Comments
Want to join the conversation?
Loading comments...